NVS Novartis AG Earnings and EPS analysis

EPS in 2025 (TTM): $6.91

Last Report Period Date: Jun 30, 2025

As of August 2025, according to Novartis AG's latest financial report, the company's current EPS (TTM) is $6.91. In 2024, the company recorded an earnings per share (EPS) of $5.92, which represents a decrease compared to its EPS of $7.15 in 2023. Novartis AG's earnings per share for the quarterly report ending on Jun 30, 2025 was $2.07.

NVS earnings history

Historical annual and quarterly earnings per share (EPS) data for Novartis AG
EPS (TTM)
$6.91
EPS Growth YoY (Quarterly)
29.4%
EPS (Quarterly)
$2.07
EPS Growth (Quarterly)
13.1%

The annual EPS in 2024 was $5.92, a decrease of 17.2% from $7.15 in 2023. For the quarter ending Jun 30, 2025, the EPS was $2.07, showing a 29.4% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of June 2025 is $6.91. In 2023, the annual EPS was $7.15, showing an increase of 124.1% from 2022.

NVS EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
29.4%
EPS growth YoY
-17.2%
EPS growth 3Y avg
-17.9%
EPS growth 5Y avg
2.9%

Over the last 12 months, Novartis AG has registered an EPS growth of 29.4% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of -17.9% per year over the past 3 years. Over the last 5 years, the company had an average EPS growth rate of 2.9%. A 10-year view shows that NVS has seen an average EPS growth of 3.5% per year.

NVS Earnings Waterfall

Breakdown of revenue, profit and net income for Novartis AG

NVS Earnings vs Peers

What are the earnings of NVS compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
MRK Merck & Co Inc 11.34 4,728.6% 9.4% 12%
ABT Abbott Laboratories 15.77 133.8% 24.5% 29.9%
NVS Novartis AG 16.46 -17.2% -17.9% 2.9%
PFE Pfizer Inc 16.76 273.7% -28.7% -13.2%
BMY Bristol Myers Squibb Co 17.39 -213.7% N/A N/A
JNJ Johnson & Johnson 17.51 -57.9% -9.7% 0.4%
AZN Astrazeneca plc 27.27 18.2% 284.3% 34.3%
TEVA Teva Pharmaceutical Industries Ltd N/A -190% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.